Our results showing slowing of cognitive decline for the higher lanabecestat dose (50 mg vs. 20 mg) for the slow progressive group suggest that higher dose of BACE inhibition may be more effective over a 24-month treatment period, as in the AMARANTH trial. Here, BACE1 is linked to Mental deterioration.